Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) - Total Liabilities
Based on the latest financial reports, Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) has total liabilities worth CN¥1.43 Billion CNY (≈ $208.76 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Shandong Jincheng Pharmaceutical and Che (300233) net asset momentum to track the company's year-over-year net asset growth rate.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300233 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Jincheng Pharmaceutical and Chemical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Iperionx Ltd
AU:IPX
|
Australia | AU$12.59 Million |
|
Shinyoung Securities Co. Ltd.
KO:001720
|
Korea | ₩10.12 Trillion |
|
ORIENT SECUR.CO.LTD.H YC1
F:OS9
|
Germany | €431.65 Billion |
|
REalloys Inc.
NASDAQ:ALOY
|
USA | $28.89 Million |
|
Dalian Sunasia Tourism Holding Co Ltd
SHG:600593
|
China | CN¥1.63 Billion |
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
China | CN¥22.52 Billion |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
Turkey | TL5.37 Billion |
|
Marimaca Copper Corp
TO:MARI
|
Canada | CA$5.59 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shandong Jincheng Pharmaceutical and Che market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Jincheng Pharmaceutical and Chemical Co Ltd (2008–2025)
The table below shows the annual total liabilities of Shandong Jincheng Pharmaceutical and Chemical Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.47 Billion ≈ $214.66 Million |
-17.26% |
| 2024-12-31 | CN¥1.77 Billion ≈ $259.42 Million |
-16.96% |
| 2023-12-31 | CN¥2.14 Billion ≈ $312.42 Million |
-1.47% |
| 2022-12-31 | CN¥2.17 Billion ≈ $317.07 Million |
+18.03% |
| 2021-12-31 | CN¥1.84 Billion ≈ $268.63 Million |
+19.76% |
| 2020-12-31 | CN¥1.53 Billion ≈ $224.30 Million |
+1.68% |
| 2019-12-31 | CN¥1.51 Billion ≈ $220.60 Million |
+25.78% |
| 2018-12-31 | CN¥1.20 Billion ≈ $175.39 Million |
+24.04% |
| 2017-12-31 | CN¥966.24 Million ≈ $141.39 Million |
+28.37% |
| 2016-12-31 | CN¥752.68 Million ≈ $110.14 Million |
+9.73% |
| 2015-12-31 | CN¥685.95 Million ≈ $100.38 Million |
+2.59% |
| 2014-12-31 | CN¥668.61 Million ≈ $97.84 Million |
+20.66% |
| 2013-12-31 | CN¥554.11 Million ≈ $81.08 Million |
+12.11% |
| 2012-12-31 | CN¥494.26 Million ≈ $72.33 Million |
+12.50% |
| 2011-12-31 | CN¥439.36 Million ≈ $64.29 Million |
-24.59% |
| 2010-12-31 | CN¥582.62 Million ≈ $85.26 Million |
+41.74% |
| 2009-12-31 | CN¥411.04 Million ≈ $60.15 Million |
+0.33% |
| 2008-12-31 | CN¥409.67 Million ≈ $59.95 Million |
-- |
About Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin pharmaceutical intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. The company was founded in 2004 and is based in Zibo, China.